• AIM ImmunoTech completed enrollment in the Phase 2 DURIPANC trial testing Ampligen with AstraZeneca’s Imfinzi in metastatic pancreatic cancer.
• Interim results have already been presented as positive, citing encouraging clinical observations with no significant toxicity reported.
• The primary endpoint analysis is scheduled to begin in December 2026, with topline results expected in Q1 2027.
• Secondary assessments, including progression-free survival and overall survival, are expected to start in June 2027.
• The readouts are positioned to guide Phase 3 planning and a potential registration-focused pivotal study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606240829PRIMZONEFULLFEED9751376) on June 24, 2026, and is solely responsible for the information contained therein.